Trial Profile
Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs WASp gene therapy (Primary)
- Indications Wiskott-Aldrich syndrome
- Focus First in man; Therapeutic Use
- Sponsors Genethon
- 19 Nov 2019 Status changed from recruiting to completed.
- 21 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 21 May 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.